Dynamic contrast enhanced MRI monitoring of primary proton and carbon ion irradiation of prostate cancer using a novel hypofractionated raster scan technique

• Verfasst von: Bonekamp, David [VerfasserIn]
• Verfasst von: Wolf, Maya Barbara [VerfasserIn]
• Verfasst von: Edler, Christopher [VerfasserIn]
• Verfasst von: Katayama, Sonja [VerfasserIn]
• Verfasst von: Schlemmer, Heinz-Peter [VerfasserIn]
• Verfasst von: Herfarth, Klaus [VerfasserIn]
• Verfasst von: Röthke, Matthias C. [VerfasserIn]
• Titel: Dynamic contrast enhanced MRI monitoring of primary proton and carbon ion irradiation of prostate cancer using a novel hypofractionated raster scan technique
• Verf.angabe: David Bonekamp, Maya B. Wolf, Christopher Edler, Sonja Katayama, Heinz-Peter Schlemmer, Klaus Herfarth, Matthias Röthke
• E-Jahr: 2016
• Jahr: 26 May 2016
• Umfang: 7 S.
• Teil: volume:120
• Teil: year:2016
• Teil: number:2
• Teil: pages:313-319
• Teil: extent:7
• Fussnoten: Gesehen am 14.05.2020
• Titel Quelle: Enthalten in: Radiotherapy and oncology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1983
• Jahr Quelle: 2016
• Band/Heft Quelle: 120(2016), 2, Seite 313-319
• ISSN Quelle: 1879-0887
• DOI: doi:10.1016/j.radonc.2016.05.012
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Carbon ion irradiation
• Sach-SW: Dynamic contrast enhanced MRI
• Sach-SW: Particle irradiation
• Sach-SW: Prostate cancer
• Sach-SW: Proton irradiation
• Sach-SW: Radiation therapy
• K10plus-PPN: 1698248695

Abstract

Purpose - To characterize parametric changes measured by sequential dynamic contrast enhanced perfusion MRI (DCE-MRI) during primary proton and carbon ion irradiation of prostate cancer using a novel hypofractionated raster scan technique to determine the potential of pharmacokinetic analysis for monitoring treatment effects of this novel irradiation scheme. - Materials and methods - Ninety-two patients were evaluated prospectively with DCE-MRI at baseline, day 10 during therapy, and 6weeks, 6months and 18months after treatment completion. After motion correction and co-registration to morphological T2-weighted images, tumors and normal appearing contralateral parenchyma (NACP) were segmented manually on T2W images and ROI statistics calculated for pharmacokinetic parameters Ktrans, kep and ve using the standard Tofts model. - Results - The volume transfer constant (Ktrans, p<0.001/p=0.010) and the leakage space partial volume (ve, p<0.001/p=0.005) showed a statistically significant increase during therapy with protons and carbon ions, respectively. Parametric increases occurred only in patients naive to antihormonal therapy (AHT), and were maximal 10days after the begining of treatment. The rate constant (kep) showed a significant increase only for proton, but not for carbon irradiation (p=0.021). Statistically significant differences between PC and NACP were observed for all parameters (p<0.001). AHT naïve patients with persistent PSA elevation above 1ng/ml at 12months experienced statistically significant elevation of Ktrans and ve compared to those with PSA suppression (p=0.04/p=0.023). - Conclusion - DCE parametric changes following ion particle irradiation of the prostate have not been previously reported. Their development into potential non-invasive imaging biomarkers for assessment of treatment response and efficacy is expected to be aided by the data on the magnitude and temporal evolution of parametric responses of cancer and normal tissue during and after therapy presented here, especially the changes of Ktrans and ve during therapy and their different measurement levels within tumors and in normal appearing contralateral tissue.